This site is intended for Healthcare professionals only.

Jubilant gets USFDA nod for Drax Exametazime


Jubilant gets USFDA nod for Drax Exametazime

New Delhi: Drug firm Jubilant Life Sciences on Monday said it has received new drug application approval from the US health regulator for Drax Exametazime.

Jubilant Pharma Ltd, a wholly-owned subsidiary of the company, through its Canada-based arm Jubilant Draximage Inc has received new drug application (NDA) approval from the United States Food and Drug Administration (USFDA) for Drax Exametazime, Jubilant Life Sciences said.

“This approved NDA is indicated for leukocyte (white blood cell) labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease,” it said in a BSE filing.

This is the sixth approval the company has received from the USFDA during the current financial year, it added.



Source: PTI
0 comment(s) on Jubilant gets USFDA nod for Drax Exametazime

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted